Dados B3 › PGMN3 × RADL3
PGMN3 × RADL3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | PGMN3 | RADL3 | year |
|---|---|---|---|
| ROE | 9.0% | 18.9% | 2025 |
| ROIC | 20.0%! | 24.8% | 2025 |
| ROA | 2.8% | 5.5% | 2025 |
| Gross margin | 32.0% | 29.3% | 2025 |
| EBIT margin | 5.8% | 6.2% | 2025 |
| Net margin | 1.8% | 2.9% | 2025 |
| Net debt/EBITDA | 1.12x | 0.69x | 2025 |
| Current ratio | 1.59x | 1.46x | 2025 |
| Revenue growth (1y) | 17.9% | 13.8% | 2025 |
| Revenue growth (5y CAGR) | 16.8%! | 17.1% | 2025 |
| Piotroski F-Score | 6/9 | 5/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | PGMN3 | RADL3 | year |
|---|---|---|---|
| P/E | 17.66x | 32.24x | 2025 |
| P/B | 1.49x | 5.71x | 2025 |
| EV/EBITDA | 4.43x | 9.37x | 2025 |
| FCF yield | -1.3% | 2.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 15:40 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.